Shanghai Sine Promod Pharmaceutical Chooses Aptar Pharma’s Twister DPI for Asthma Therapy

April 10, 2015
Pharmaceutical Technology Editors

Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI.

Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI. Budesonide, an inhaled corticosteroid for maintenance therapy in patients with asthma, is the first product marketed with Aptar Pharma’s Twister technology. The product is marketed in two forms, one containing 30 capsules and the other with 60 capsules. Each capsule consists of 200 mcg of budesonide blended with lactose monohydrate as the carrier.

Aptar Pharma developed Twister, which is a new capsule-based DPI, to address unmet medical needs in fast-growing asthma and COPD markets. The design of Twister is simple and robust, with few components to ensure cost-effective production. The technology has been tested and validated with a number of different dry powder drug formulations.

Twister has been designed to be patient-friendly and easy to use, allowing patients easy access to their medication in three simple steps: insert, twist, and inhale. The DPI is transparent, hence, allowing the capsule and powder to be seen in the device as they are administered, this feature was designed as a means to improve patient compliance by providing visual cues. In addition, the patient is also guided by audible feedback during inhalation.

Source: Aptar Pharma